Guided Therapeutics, Inc. Submits First Module of Premarket Approval Application for Painless Cervical Cancer Detection to FDA

Published: Dec 10, 2008

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) today announced it submitted the first of three modules of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the LightTouchTM non-invasive cervical cancer detection device.

Back to news